The effect of indicators of CALLY index on survival in glioblastoma.
Glioblastoma
Systemic Immune-Inflammation Index
Systemic Inflammatory Response Index
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
received:
23
02
2024
accepted:
09
03
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
1
4
2024
Statut:
aheadofprint
Résumé
Glioblastoma is the most common primary brain tumor in adults. Recently, research has been published on the potential prognostic indicators associated with different types of cancer. Due to the limited availability of data investigating the relationship between the CALLY index and glioblastoma patients, we aimed to conduct this study. Between January 2017 and December 2023, we conducted a study on patients diagnosed with glioblastoma. We collected demographic data and routine laboratory tests at the time of admission. To calculate the CALLY index, we used the formula (albumin value × lymphocyte count) / CRP value × 104. Parameters were compared for in-hospital mortality across different groups. The study analyzed 202 patients who met the inclusion criteria. Of these, 165 (81.7%) were classified as "survivors" and 37 (18.3%) as "deceased." A comparison of hematologic parameters between the two groups showed a significantly lower CALLY index in the "deceased" group (3.05 (4.92)) compared to the "survivor" group (10.13 (13.69)) (p < 0.001). The study compared the parameters between groups with regard to in-hospital mortality. Based on the results of the study, we conclude that the CALLY index can be considered an easily applicable indicator for the mortality of glioblastoma patients.
Identifiants
pubmed: 38561591
doi: 10.1007/s11845-024-03666-w
pii: 10.1007/s11845-024-03666-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.
Références
Mermut O, Inanc B (2020) The effect of indicators of systemic inflammatory response on survival in glioblastoma multiforme. Turk Neurosurg 30(5):658–665. https://doi.org/10.5137/1019-5149.JTN.27068-19.1
doi: 10.5137/1019-5149.JTN.27068-19.1
pubmed: 32530473
Bambury RM, Teo MY, Power DG et al (2013) The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 114(1):149–154. https://doi.org/10.1007/s11060-013-1164-9
doi: 10.1007/s11060-013-1164-9
pubmed: 23780645
Jarmuzek P, Kozlowska K, Defort P et al (2023) Prognostic values of systemic inflammatory immunological markers in glioblastoma: a systematic review and meta-analysis. Cancers (Basel) 15(13):3339. https://doi.org/10.3390/cancers15133339
doi: 10.3390/cancers15133339
pubmed: 37444448
Tan AC, Ashley DM, López GY et al (2020) Management of glioblastoma: state of the art and future directions. CA Cancer J Clin 70(4):299–312. https://doi.org/10.3322/caac.21613
doi: 10.3322/caac.21613
pubmed: 32478924
Weng W, Chen X, Gong S et al (2018) Preoperative neutrophil-lymphocyte ratio correlated with glioma grading and glioblastoma survival. Neurol Res 40(11):917–922. https://doi.org/10.1080/01616412.2018.1497271
doi: 10.1080/01616412.2018.1497271
pubmed: 30074469
Ji F, Fu S, Guo Z et al (2016) Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection. Oncotarget 7(44):72276–72289. https://doi.org/10.18632/oncotarget.10848
doi: 10.18632/oncotarget.10848
pubmed: 27472390
pmcid: 5342161
Förnvik K, Maddahi A, Liljedahl E et al (2021) What is the role of CRP in glioblastoma? Cancer Treat Res Commun 26:100293. https://doi.org/10.1016/j.ctarc.2020.100293
doi: 10.1016/j.ctarc.2020.100293
pubmed: 33385735
Topkan E, Kucuk A, Ozdemir Y et al (2020) Systemic inflammation response index predicts survival outcomes in glioblastoma multiforme patients treated with standard Stupp protocol. J Immunol Res 2020:8628540. https://doi.org/10.1155/2020/8628540
doi: 10.1155/2020/8628540
pubmed: 33274245
pmcid: 7683150
Yang C, Hu BW, Tang F et al (2022) Prognostic value of Systemic Immune-Inflammation Index (SII) in patients with glioblastoma: a comprehensive study based on meta-analysis and retrospective single-center analysis. J Clin Med 11(24):7514. https://doi.org/10.3390/jcm11247514
doi: 10.3390/jcm11247514
pubmed: 36556130
pmcid: 9787672
Chen N, Peng C, Li D (2022) Epigenetic underpinnings of inflammation: a key to unlock the tumor microenvironment in glioblastoma. Front Immunol 13:869307. https://doi.org/10.3389/fimmu.2022.869307
doi: 10.3389/fimmu.2022.869307
pubmed: 35572545
pmcid: 9100418
Massara M, Persico P, Bonavita O et al (2017) Neutrophils in glioma. Front Immunol 8:1349. https://doi.org/10.3389/fimmu.2017.01349
doi: 10.3389/fimmu.2017.01349
pubmed: 29123517
pmcid: 5662581
Zhou Y, Xiao D, Jiang X, Nie C (2023) EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma. J Transl Med 21(1):28. https://doi.org/10.1186/s12967-023-03883-4
doi: 10.1186/s12967-023-03883-4
pubmed: 36647156
pmcid: 9843967
Chen J, Wang H, Deng C, Fei M (2023) SLC12A5 as a novel potential biomarker of glioblastoma multiforme. Mol Biol Rep 50(5):4285–4299. https://doi.org/10.1007/s11033-023-08371-y
doi: 10.1007/s11033-023-08371-y
pubmed: 36917367
Litak J, Mazurek M, Grochowski C et al (2019) PD-L1/PD-1 Axis in glioblastoma multiforme. Int J Mol Sci 20(21):5347. https://doi.org/10.3390/ijms20215347
doi: 10.3390/ijms20215347
pubmed: 31661771
pmcid: 6862444
Yang M, Lin SQ, Liu XY et al (2023) Association between C-reactive protein-albumin-lymphocyte (CALLY) index and overall survival in patients with colorectal cancer: from the investigation on nutrition status and clinical outcome of common cancers study. Front Immunol 14:1131496. https://doi.org/10.3389/fimmu.2023.1131496
doi: 10.3389/fimmu.2023.1131496
pubmed: 37063910
pmcid: 10098202
Lida H, Tani M, Komeda K et al (2022) Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma. HPB (Oxford) 24(1):101–115. https://doi.org/10.1016/j.hpb.2021.06.414
doi: 10.1016/j.hpb.2021.06.414
Witthayanuwat S, Pesee M, Supaadirek C et al (2018) Survival analysis of glioblastoma multiforme. Asian Pac J Cancer Prev 19(9):2613–2617. https://doi.org/10.22034/APJCP.2018.19.9.2613
doi: 10.22034/APJCP.2018.19.9.2613
pubmed: 30256068
pmcid: 6249474
Shi X, Li H, Xu Y et al (2022) The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients. Neurol Sci 43(9):5523–5531. https://doi.org/10.1007/s10072-022-06158-w
doi: 10.1007/s10072-022-06158-w
pubmed: 35606674
pmcid: 9126244
Ha ET, Antonios JP, Soto H et al (2014) Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment. Neuroimmunol Neuroinflammation 1(2):66–76
doi: 10.4103/2347-8659.139717
Killock D (2020) Extent of resection is important across glioblastoma molecular subtypes. Nat Rev Clin Oncol 17(5):275. https://doi.org/10.1038/s41571-020-0344-8
doi: 10.1038/s41571-020-0344-8
pubmed: 32203273